Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 2 selected

Type

Guidance programme 11 selected

Guidance programme

Showing 41 to 50 of 1050

TitleReference numberPublishedLast updated
Tirzepatide for treating type 2 diabetesTA924
Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and overTA1093
Guselkumab for treating moderately to severely active ulcerative colitisTA1094
Guselkumab for previously treated moderately to severely active Crohn's diseaseTA1095
Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancerTA1092
Tarlatamab for extensive-stage small-cell lung cancer after 2 or more treatmentsTA1091
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinomaTA1090
Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and overTA1088
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more treatments (terminated appraisal)TA1089
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive HER2-negative early breast cancer at high risk of recurrenceTA1086

Results per page

  1. 10
  2. 25
  3. 50
  4. All